Advertisements


Progenics advances prostrate cancer treatment to phase 2 after FDA discussions

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Cover story: Immunotherapy advances treatment in various types of cancer

Like a gas and brake pedal in a car, two different aspects of immunotherapy work simultaneously to thwart various types of cancer......»»

Category: topSource: bizjournalsNov 30th, 2018

Merck"s Keytruda Improves Survival in Esophageal Cancer Study

Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer. Merck & Co., Inc. MRK annou.....»»

Category: dealsSource: nytNov 15th, 2018

Progenics Pharma"s Stock Down on Dismal Phase III Study Data

Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection. .....»»

Category: worldSource: nytSep 20th, 2018

CTI BioPharma says trial of treatment for non-Hodgkin lymphoma failed to meet main goals

CTI BioPharma Corp. said Monday a late-stage trial of a treatment for the blood cancer non-Hodgkin lymphoma failed to meet its main goals. The Phase III trial evaluating Pixuvri combined with rituximab in comparison to gemcitabine combin.....»»

Category: topSource: marketwatchJul 9th, 2018

Merck Moves Ahead With Late-Stage Trial Win

Shares of Merck had a boost early Monday after the firm announced that its Phase 3 trial of Keytruda for the treatment of metastatic non-small cell lung cancer met its primary endpoint......»»

Category: blogSource: 247wallstApr 9th, 2018

Merck"s stock surges after positive Keytruda trial results

Shares of Merck & Co. Inc. surged 2.6% in premarket trade Monday, after the drug maker said its cancer treatment Keytruda met the primary endpoint of a phase 3 trial evaluating the Keytr.....»»

Category: topSource: marketwatchApr 9th, 2018

Rexahn sees Phase 2 RX-3117 study in advanced bladder cancer data next year

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 6th, 2018

AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study

IDMC recommends AbbVie (ABBV) to stop enrolment in a.....»»

Category: worldSource: nytDec 6th, 2018

Does Keytruda"s Dominance Make Merck & Co. a Buy Now?

Can an unstoppable cancer treatment help this big pharma stock outperform for your portfolio?.....»»

Category: topSource: foxnewsDec 3rd, 2018

Progenics announces first patient dosed in Phase 3 CONDOR study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 3rd, 2018

Shares of Fate Therapeutics up 4.1% in premarket trade after FDA accepts IND application for potential cancer treatment

Shares of Fate Therapeutics were up 4.1% in premarket trade.....»»

Category: topSource: marketwatchNov 30th, 2018

Cover story: In battling cancer, technologies shave days to save lives

A look at how local medical centers are deploying innovative technologies, albeit in different forms, to expedite the treatment of cancer using improved or newly developed medical advancements. Prognosis: positive......»»

Category: topSource: bizjournalsNov 30th, 2018

Cover story: Docs tackle colon cancer with robotics, precision

Colorectal cancers kill more than 50,000 Americans each year, but advances in robotic surgery are improving surgical outcomes and reducing long recovery times......»»

Category: topSource: bizjournalsNov 30th, 2018

Alkermes reports positive results in trial of schizophrenia treatment that reduces weight gain

Alkermes Plc announced positive results Thursday for a trial of its ALKS 3832 treatment for schizophrenia. The Phase 3 tr.....»»

Category: topSource: marketwatchNov 29th, 2018

PHOTOS: How this $1M donation at Levine Children"s Hospital aids treatment of rare cancer

Levine Children's Hospital now has a specialized treatment suite for an aggressive form of childhood cancer, thanks to a $1 million donation from the Isabella Santos Foundation. The suite is equipped for MIBG treatment, which uses radiation to ta.....»»

Category: topSource: bizjournalsNov 29th, 2018

YouTube"s prostate cancer advice may be dangerous, misleading, study finds

Popular YouTube videos on prostate cancer often mislead patients seeking medical screening and treatment information, according to a new study led by researchers at NYU School of Medicine and its... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkNov 28th, 2018

Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate

Alnylam (ALNY) and Vir commence phase I/II study for VIR-2218 for the treatment of chron.....»»

Category: dealsSource: nytNov 27th, 2018

Bristol-Myers Squibb shares decline on failed lung-cancer drug study

Bristol-Myers Squibb Co. shares declined in the extended session Monday after the drug maker said a lung-cancer treatment.....»»

Category: topSource: marketwatchNov 26th, 2018

Corcept Initiates Phase III Study for Cushing"s Syndrome

Corcept (CORT) doses first patient in the phase III study of relacorilant for the treatment of Cushing's syndrome. Corcept Therapeutics Inc. CORT announced that it has do.....»»

Category: worldSource: nytNov 20th, 2018

Pfizer"s Bavencio Phase III Study for Ovarian Cancer Fails

Zacks.....»»

Category: topSource: redinewsNov 20th, 2018